Drugs / CD19/20 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04723914 | Oct 2020 → Dec 2022 | B-cell non-Hodgkin lymphoma | YuLi | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/20 CAR-T cells | “Patients with R/R B-NHL received CD19/20 CAR-T cells following lymphodepletion.” PMID 42144261 ↗ May 2026 |
| Modality | Cell therapy | “bispecific CD19/20 CAR-T cells” PMID 42144261 ↗ May 2026 |
| Target | CD19 | “Dual targeting of CD19 and CD20 may mitigate antigen loss.” PMID 42144261 ↗ May 2026 |
| Target | CD20 | “Dual targeting of CD19 and CD20 may mitigate antigen loss.” PMID 42144261 ↗ May 2026 |